Corbus Pharmaceuticals Holdings, Inc. (CRBP)
$36.53
Insights on Corbus Pharmaceuticals Holdings, Inc.
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 273.1%
Performance
- $35.19$37.78$36.53
3.67%
Downside
Day's Volatility :6.86%
Upside
3.31%
- $3.03$49.87$36.53
91.71%
Downside
52 Weeks Volatility :93.92%
Upside
26.75%
Returns
| Period | Corbus Pharmaceuticals Holdings, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 436.99% | -0.7% | 0.0% |
6 Months | 519.33% | 6.6% | 0.0% |
1 Year | 209.67% | 3.7% | -1.5% |
3 Years | -24.47% | 14.0% | -21.8% |
Highlights
Market Capitalization | 432.1M |
Book Value | - $1.56 |
Earnings Per Share (EPS) | -10.31 |
PEG Ratio | 0.0 |
Wall Street Target Price | 55.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -59.57% |
Return On Equity TTM | -341.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -16.1M |
EBITDA | -44.4M |
Diluted Eps TTM | -10.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.2 |
EPS Estimate Next Year | -5.12 |
EPS Estimate Current Quarter | -2.36 |
EPS Estimate Next Quarter | -1.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 50.56%
Technicals Summary
Sell
Neutral
Buy
Corbus Pharmaceuticals Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Corbus Pharmaceuticals Holdings, Inc. | -10.72% | 519.33% | 209.67% | -24.47% | -82.41% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Corbus Pharmaceuticals Holdings, Inc. | NA | NA | 0.0 | -5.2 | -3.42 | -0.6 | NA | -1.56 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Corbus Pharmaceuticals Holdings, Inc. | Buy | $432.1M | -82.41% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Ikarian Capital, LLC
1.90%Vanguard Group Inc
1.74%Sio Capital Management, LLC
1.45%BlackRock Inc
0.78%BOOTHBAY FUND MANAGEMENT, LLC
0.40%Geode Capital Management, LLC
0.37%
Corporate Announcements
Corbus Pharmaceuticals Holdings, Inc. Earnings
Corbus Pharmaceuticals Holdings, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Organization | Corbus Pharmaceuticals Holdings, Inc. |
Employees | 19 |
CEO | Dr. Yuval Cohen Ph.D. |
Industry | Health Technology |
